IRIS PubliCatt

Cauda, Roberto
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 13.045
NA - Nord America 11.627
AS - Asia 4.394
SA - Sud America 64
AF - Africa 50
Continente sconosciuto - Info sul continente non disponibili 24
OC - Oceania 24
Totale 29.228
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.505
DE - Germania 4.342
CN - Cina 2.350
SE - Svezia 2.089
IT - Italia 1.513
PL - Polonia 1.129
UA - Ucraina 1.127
SG - Singapore 987
FR - Francia 923
IE - Irlanda 594
GB - Regno Unito 465
ID - Indonesia 362
FI - Finlandia 296
IN - India 260
RU - Federazione Russa 251
TR - Turchia 248
BE - Belgio 86
CA - Canada 73
IR - Iran 52
NL - Olanda 50
HK - Hong Kong 41
JP - Giappone 40
AT - Austria 36
MX - Messico 31
BR - Brasile 27
CH - Svizzera 22
CI - Costa d'Avorio 22
EU - Europa 22
AU - Australia 21
BG - Bulgaria 15
VN - Vietnam 15
CZ - Repubblica Ceca 14
ES - Italia 14
BZ - Belize 13
LT - Lituania 11
CO - Colombia 10
GR - Grecia 10
RO - Romania 9
AR - Argentina 8
CL - Cile 8
EG - Egitto 8
PT - Portogallo 8
EC - Ecuador 7
MA - Marocco 7
KR - Corea 6
MY - Malesia 6
AL - Albania 5
DK - Danimarca 5
HU - Ungheria 5
PH - Filippine 5
VA - Santa Sede (Città del Vaticano) 5
NG - Nigeria 4
TW - Taiwan 4
AE - Emirati Arabi Uniti 3
BY - Bielorussia 3
EE - Estonia 3
MO - Macao, regione amministrativa speciale della Cina 3
NO - Norvegia 3
NZ - Nuova Zelanda 3
PA - Panama 3
BD - Bangladesh 2
BN - Brunei Darussalam 2
ET - Etiopia 2
HR - Croazia 2
KE - Kenya 2
LU - Lussemburgo 2
LV - Lettonia 2
PE - Perù 2
ZA - Sudafrica 2
A1 - Anonimo 1
A2 - ???statistics.table.value.countryCode.A2??? 1
AZ - Azerbaigian 1
BO - Bolivia 1
CY - Cipro 1
GA - Gabon 1
GE - Georgia 1
GL - Groenlandia 1
IQ - Iraq 1
IS - Islanda 1
KW - Kuwait 1
KZ - Kazakistan 1
ME - Montenegro 1
MK - Macedonia 1
MM - Myanmar 1
MT - Malta 1
PK - Pakistan 1
PR - Porto Rico 1
SC - Seychelles 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
UG - Uganda 1
VE - Venezuela 1
Totale 29.228
Salva come PNG Salva come JPEG
Città #
Chandler 2.407
Ashburn 915
Singapore 756
Jacksonville 752
Hangzhou 630
Dublin 585
Warsaw 583
San Mateo 568
Kraków 542
Nanjing 434
Ann Arbor 394
New York 388
Jakarta 360
Dearborn 353
Wilmington 342
Houston 310
Woodbridge 309
Nürnberg 294
Milan 244
Izmir 227
Boston 220
Lawrence 185
Redmond 185
Cattolica 181
Fairfield 181
Moscow 179
Beijing 173
Nanchang 173
Seattle 165
Rome 152
Marseille 151
Princeton 151
Redwood City 136
Lancaster 123
Bremen 109
Munich 105
Shenyang 101
Boardman 100
Kunming 89
Brussels 80
Mountain View 75
Hebei 73
Norwalk 71
Los Angeles 67
University Park 63
Cambridge 62
Tianjin 61
Fremont 59
Chicago 58
Changsha 55
Leawood 53
Jiaxing 49
Zhengzhou 45
Augusta 44
Helsinki 42
Pune 42
Guangzhou 41
Shanghai 41
Jinan 37
Hong Kong 36
Verona 36
San Jose 34
London 33
Simi Valley 32
Vienna 32
Washington 31
Ottawa 29
Toronto 28
Philadelphia 25
Hefei 24
Abidjan 22
Amsterdam 22
Kish 21
Buffalo 20
Falls Church 20
Andover 19
Edinburgh 19
Casalecchio di Reno 17
Changchun 17
Lanzhou 17
Auburn Hills 15
Detroit 15
Ningbo 15
Paris 15
Frankfurt am Main 14
Belize City 13
Fuzhou 13
Phoenix 13
Tokyo 13
Busto Arsizio 12
Las Vegas 12
Bologna 11
Cuauhtémoc 11
São Paulo 11
Chengdu 10
Costa Mesa 10
Santa Clara 10
Taizhou 10
Bari 9
Naples 9
Totale 16.145
Salva come PNG Salva come JPEG
Nome #
New classification for the treatment of pyogenic spondylodiscitis: validation study on a population of 250 patients with a follow-up of 2 years 352
Risk factors and outcomes of candidemia caused by biofilm-forming isolates in a tertiary care hospital 333
Novel sensitive, specific and rapid pharmacogenomic test for the prediction of abacavir hypersensitivity reaction: HLA-B*57:01 detection by real-time PCR 320
Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy 310
Factors associated with mortality in bacteremic patients with hematologic malignancies. 300
Factors associated with mortality in bacteremic patients with haematologic malignancies 299
Risk factors and outcomes of candidemia caused by biofilm-forming isolates in a tertiary care hospital 298
Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy 276
Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. 256
Antibodies against a β-glucan-protein complex of Candida albicans and its potential as indicator of protective immunity in candidemic patients 217
Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. 215
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 211
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study) 210
La pandemia di COVID-19: un limite o una frontiera per la Legge 24/2017? 198
Predictors of Mortality in Bloodstream Infections Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae: Importance of Combination Therapy 193
Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility 176
Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis 175
Biofilm production by Candida species and inadequate antifungal therapy as predictors of mortality for patients with candidemia. 174
Prevalence of osteoporosis and predictors of low BMD in a cohort of HIV-1-infected patients in Rome: features of a population at high risk 170
Factors associated with mortality in bacteremic patients with hematologic malignancies. 166
Liver fibrosis is associated with cognitive impairment in HIV-positive patients 165
Costs of bloodstream infections caused by Escherichia coli and influence of extended-spectrum-beta-lactamase production and inadequate initial antibiotic therapy. 163
Fungaemia caused by Candida glabrata with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome 163
Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre 160
Evaluation of emotion processing in HIV-infected patients and correlation with cognitive performance 151
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study) 151
Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection 151
Identifying patients harboring extended-spectrum-beta-lactamase-producing Enterobacteriaceae on hospital admission: derivation and validation of a scoring system. 150
Risk factors and outcomes of candidemia caused by biofilm-forming isolates in a tertiary care hospital 148
Asthma in patients admitted to emergency department for COVID-19: prevalence and risk of hospitalization 147
Antibiotic usage and risk of colonization and infection with antibiotic-resistant bacteria: a hospital population-based study 141
Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia 140
Bloodstream infections caused by extended-spectrum-beta-lactamase- producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy. 140
Bloodstream infections caused by extended-spectrum-beta-lactamase- producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy 139
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2 years follow-up in HIV-infected patients 139
Vancomycin versus cefazolin prophylaxis for cerebrospinal shunt placement in a hospital with a high prevalence of meticillin-resistant Staphylococcus aureus 134
Neuropsychological screening tools in Italian HIV+ patients: a comparison of Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE) 134
Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients 133
Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010. 132
Serum of healthy donors receiving granulocyte colony-stimulating factor induces T cell unresponsiveness 130
Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies 130
Relationship between antiretroviral plasma concentration and emergence of HIV-1 resistance mutations at treatment failure 129
Valutazione costo-efficacia del percorso dei pazienti a rischio di epatite B sottoposti a test anti-HBV 126
Impact of highly active antiretroviral therapy (HAART) on the incidence of bacterial infections in HIV infected subjects 125
Variability of raltegravir plasma levels in the clinical setting 125
Changes in incidence and risk factors of Mycobacterium avium complex infections in patients with AIDS in the era of new antiretroviral therapies 124
Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies 123
Ophthalmic artery resistance index IS increased in HIV-Infected patients and is influenced by protease inhibitors exposure 123
Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen. 122
Risk factors and predictors of mortality of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in HIV-infected patients 122
Nosocomial bacterial pneumonia in human immunodeficiency virus infected subjects: incidence, risk factors and outcome 121
Infection control and prevention measures to reduce the spread of vancomycin-resistant enterococci in hospitalized patients: a systematic review and meta-analysis 121
Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial 120
Predictive models for identification of hospitalized patients harboring KPC-producing Klebsiella pneumoniae 120
Costs of bloodstream infections caused by Escherichia coli and influence of extended-spectrum-beta-lactamase production and inadequate initial antibiotic therapy 116
Attitudes and practices of dentists treating HIV patients in HAART era. 115
Prospective evaluation of epidemiological, clinical, and microbiological features of pandemic influenza A (H1N1) virus infection in Italy 115
Analysis of the risk factors associated with the emergence of azole resistant oral candidosis in the course of HIV infection 115
Testimonianze dalle periferie del mondo. Sei anni di Charity Work Program Quaderni del CeSI Edizione Vita e Pensiero . 114
The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case-control study 112
Attitudes and practices of dentists treating patients infected with human immunodeficiency virus in the era of highly active antiretroviral therapy 111
Hospital-acquired candidemia in HIV-infected patients. Incidence, risk factors and predictors of outcome. 110
Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction 109
Clinical presentation, microbiological features and correlates of disease severity of 2009 pandemic influenza A (H1N1) infection 108
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients 108
Initial antifungal strategy does not correlate with mortality in patients with candidemia 108
A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19 108
Evaluation of efficacy, pharmacokinetics and tolerability of peptidomimetic aspartic proteinase inhibitors as cream formulation in experimental vaginal candidiasis 107
Verbal list learning and memory profiles in HIV-infected adults, Alzheimer's disease, and Parkinson's disease: An evaluation of the "cortical hypothesis" of NeuroAIDS 107
Bacterial pneumonia in HIV-infected patients: analysis of risk factors and prognostic indicators 106
Comparison of expression vectors in Lactobacillus reuteri strains 106
Predictors of successful genotype-guided antiretroviral therapy in treatment-experienced individuals over calendar year: a cohort study 106
The effect of polymorphisms in candidate genes on the long-term risk of lipodystrophy and dyslipidemia in HIV-infected white patients starting antiretroviral therapy 106
Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy 106
Cardiovascular risk factors and carotid intima-media thickness are associated with low cognitive performance in HIV-infected patients 105
Infection control and prevention measures to reduce the spread of vancomycin-resistant enterococci in hospitalized patients, a systematic review and meta-analysis 105
Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection 105
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study 105
Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure. 103
Evaluation of the new VITEK 2 extended-spectrum beta-lactamase (ESBL) test for rapid detection of ESBL production in Enterobacteriaceae isolates 103
Prediction models to identify hospitalized patients at risk of being colonized or infected with multidrug-resistant Acinetobacter baumannii calcoaceticus complex. 102
Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: two years experience in routine clinical practice 102
Older age does not influence CD4 cell recovery in HIV-1 infected patients receiving highly active antiretroviral therapy 102
Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study 102
Multidrug-resistant Proteus mirabilis bloodstream infections: risk factors and outcomes 102
Bloodstream infections caused by extended -spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome 101
Consensus document on controversial issues in the treatment of complicated skin and skin-structure infections 101
Cognitive reserve and neuropsychological functioning in older HIV-infected people 101
Psychopathological profile in COVID-19 patients including healthcare workers: the implications 100
Effect of aging and human immunodeficiency virus infection on cognitive abilities 100
Comparison of cognitive performance in HIV or HCV mono-infected and HIV-HCV co-infected patients 100
Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study 100
Trimethoprim-sulfamethoxazole therapy for patients with carbapenemase-producing Klebsiella pneumoniae infections: retrospective single-center case series 100
Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: risk factors and mortality. 99
Are mutations in HIV type-1 reverse transcriptase 245 codon predictive of abacavir hypersensitivity reaction? 98
Virological suppression reduces clinical progression in patients with multiclass-resistant HIV type 1 98
Macrophage chemoattractant protein-1 levels in cerebrospinal fluid correlate with containment of JC virus and prognosis of acquired immunodeficiency syndrome--associated progressive multifocal leukoencephalopathy. 98
Effects of antiretroviral therapy on tube-like network formation of human endothelial cells. 98
Resource-saving advice from an infectious diseases specialist team in a large university hospital: an exportable model? 98
HIV-associated bacterial pneumonia in the era of highly active antiretroviral therapy 97
Totale 14.309
Salva come PNG Salva come JPEG
Categoria #
all - tutte 116.668
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 116.668
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.502 0 0 0 0 335 418 357 167 287 250 344 344
2020/20212.721 216 292 70 269 331 173 286 61 408 124 430 61
2021/20223.160 258 258 85 241 134 109 70 517 126 222 485 655
2022/20236.590 837 944 539 960 515 741 280 522 836 122 208 86
2023/20243.131 137 876 97 246 128 517 187 97 51 104 361 330
2024/20251.610 135 202 499 207 567 0 0 0 0 0 0 0
Totale 29.597